HighVista Strategies’s Keros Therapeutics KROS Stock Holding History

HighVista Strategies’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-83,050	Closed	-$1.31M	–	166
2025 Q3	$1.31M	Buy	83,050 +30,432	+58%	+$450K	0.32%	101
2025 Q2	$702K	Buy	52,618 +511	+1%	+$6.9K	0.26%	115
2025 Q1	$531K	Hold	52,107	–	–	0.2%	126
2024 Q4	$825K	Hold	52,107	–	–	0.31%	109
2024 Q3	$3.03M	Buy	52,107 +12,899	+33%	+$637K	1.04%	29
2024 Q2	$1.79M	Hold	39,208	–	–	0.65%	49
2024 Q1	$2.6M	Buy	+39,208	New	+$2.32M	0.93%	33
2023 Q1	–	Sell	-18,616	Closed	-$894K	–	123
2022 Q4	$894K	Buy	+18,616	New	+$870K	0.53%	53
2022 Q3	–	Sell	-16,623	Closed	-$459K	–	122
2022 Q2	$459K	Buy	16,623 +583	+4%	+$25.6K	0.28%	78
2022 Q1	$872K	Buy	+16,040	New	+$823K	0.55%	49

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HighVista Strategies's KROS Position: Q4 2025 in Review

HighVista Strategies sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 83,050 shares — an estimated $1.31M sold.

HighVista Strategies first reported a position in KROS in Q1 2022 and held it in 10 quarters. The position peaked at $3.03M in Q3 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

HighVista Strategies reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
HighVista Strategies sold 83,050 Keros Therapeutics shares in Q4 2025, an estimated $1.31M.
HighVista Strategies first reported a position in Keros Therapeutics in Q1 2022 and held it in 10 quarters.
HighVista Strategies's Keros Therapeutics position peaked at $3.03M in Q3 2024.
166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.